Climb Bio, Inc. (CLYM)
| Market Cap | 503.96M +516.3% |
| Revenue (ttm) | n/a |
| Net Income | -52.79M |
| EPS | -0.79 |
| Shares Out | 47.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 985,563 |
| Open | 10.77 |
| Previous Close | 10.91 |
| Day's Range | 10.38 - 11.60 |
| 52-Week Range | 1.16 - 12.48 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 19.77 (+87.39%) |
| Earnings Date | May 7, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $19.77, which is an increase of 87.39% from the latest price.
News
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer
Climb Bio Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted progress on two antibody programs for renal and autoimmune diseases, with upcoming data at ERA and ASN. Differentiation is driven by advanced technology, global partnerships, and a focus on dosing convenience and efficacy. Regulatory and scientific trends support further development.
Climb Bio registers to sell 11.59M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholder of up to 11.59M shares of common stock. The company is not selling any…
Climb Bio Registration statement: Registration filing
Climb Bio filed a registration statement on May 29, 2026, providing details about a securities offering with the SEC.
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Climb Bio presented updates on its two lead monoclonal antibody assets targeting serious renal and hematologic diseases, with multiple clinical data readouts expected in 2024. The company highlighted differentiation in safety, dosing, and market positioning, and is well-funded to advance pivotal studies.
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, toda...
Climb Bio price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio (CLYM) to $20 from $15 and keeps a Buy rating on the shares post the Q1 report.
Climb Bio price target raised to $17 from $15 at Wedbush
Wedbush raised the firm’s price target on Climb Bio (CLYM) to $17 from $15 and keeps an Outperform rating on the shares. With Climb Bio recently convening its R&D Spotlight…
Climb Bio reports Q1 EPS (20c), consensus (31c)
“During the first quarter, we continued to execute on a focused development strategy aimed at generating clear clinical and translational data across our two programs,” said Aoife Brennan, President a...
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ER...
Climb Bio Earnings release: Q1 2026
Climb Bio released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Climb Bio Quarterly report: Q1 2026
Climb Bio has published its Q1 2026 quarterly earnings report on May 7, 2026.
Climb Bio price target raised to $21 from $12 at Baird
Baird raised the firm’s price target on Climb Bio (CLYM) to $21 from $12 and keeps an Outperform rating on the shares. The firm updated its model following its R&D…
Climb Bio price target raised to $19 from $8 at BTIG
BTIG raised the firm’s price target on Climb Bio (CLYM) to $19 from $8 and keeps a Buy rating on the shares. The company’s anti-CD19 mAb has multiple near-term data…
Climb Bio Transcript: R&D Spotlight: Budoprutug and the CD19 Opportunity
Budoprutug is advancing in pMN, ITP, and SLE with robust early data, including durable remissions and strong B-cell depletion. Key 2026 data readouts will inform dose selection, clinical efficacy, and expansion plans, with subcutaneous formulation development enhancing market potential.
Climb Bio Slides: R&D Spotlight: Budoprutug and the CD19 Opportunity
Climb Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast T...
Climb Bio initiated with a Buy at Chardan
Chardan initiated coverage of Climb Bio (CLYM) with a Buy rating and $22 price target The firm says the company is advancing two “differentiated” monoclonal antibodies targeting “validated but improva...
Climb Bio management to meet with Piper Sandler
Meeting to be held in Boston on April 30 hosted by Piper Sandler.
Climb Bio to sell 9.481M shares at $9.50 in private placement
Climb Bio (CLYM) announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate…
Climb Bio, Inc. Announces $110.0 Million Private Placement
WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
Climb Bio Proxy statement: Proxy filing
Climb Bio filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Climb Bio Proxy statement: Proxy filing
Climb Bio filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.